RG
IMVT icon

Redmile Group’s Immunovant IMVT Stock Holding History

Redmile Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-490,394
Closed -$8.38M – 53
2025
Q1 		$8.38M Sell
490,394
-81,430
-14% -$1.7M 0.79% 26
2024
Q4 		$14.2M Sell
571,824
-70,405
-11% -$2M 0.99% 29
2024
Q3 		$18.3M Sell
642,229
-77,948
-11% -$2.3M 1.08% 32
2024
Q2 		$19M Sell
720,177
-249,444
-26% -$7.1M 1.15% 32
2024
Q1 		$31.3M Sell
969,621
-7,451
-0.8% -$272K 1.15% 31
2023
Q4 		$41.2M Sell
977,072
-125,442
-11% -$4.62M 1.47% 19
2023
Q3 		$42.3M Sell
1,102,514
-818,638
-43% -$18.5M 2.01% 12
2023
Q2 		$36.4M Buy
1,921,152
+604,121
+46% +$11.3M 1.4% 23
2023
Q1 		$20.4M Buy
1,317,031
+228,900
+21% +$3.97M 0.89% 41
2022
Q4 		$19.3M Buy
+1,088,131
New +$13.7M 0.79% 37
2020
Q4 		– Sell
-120,940
Closed -$4.26M – 91
2020
Q3 		$4.26M Sell
120,940
-479,060
-80% -$14.4M 0.08% 73
2020
Q2 		$14.6M Buy
+600,000
New +$12.9M 0.27% 62

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Redmile Group's IMVT Position: Q2 2025 in Review

Redmile Group sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 490,394 shares — an estimated $8.38M sold.

Redmile Group first reported a position in IMVT in Q2 2020 and held it in 12 quarters. The position peaked at $42.3M in Q3 2023. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Redmile Group reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Redmile Group sold 490,394 Immunovant shares in Q2 2025, an estimated $8.38M.
  • Redmile Group first reported a position in Immunovant in Q2 2020 and held it in 12 quarters.
  • Redmile Group's Immunovant position peaked at $42.3M in Q3 2023.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Redmile Group's 13F filing for Q2 2025, filed 14 Aug 2025.